Literature DB >> 29516280

Serum BAFF in Indian patients with IIM: a retrospective study reveals novel clinico-phenotypic associations in children and adults.

Latika Gupta1, Smriti Chaurasia1, Puja Srivastava1, Sanjay Dwivedi1, Able Lawrence1, Ramnath Misra2.   

Abstract

We studied the serum levels of B cell survival factors BAFF and APRIL in patients with idiopathic inflammatory myositis (IIM) and their relation with clinical and autoantibodies. Seventy-five patients (51 females and 24 males) with IIM (Bohan and Peter's criteria 1975) and 25 healthy adults were analyzed for BAFF, APRIL and IL-17 by ELISA, and myositis-specific and associated antibodies (MSA and MAA) using line immunoblot assay. Of the 75 patients, 59 were adults, 42 had Dermatomyositis (DM), and 17 had Polymyositis. Median disease duration was 5 (3-12) months. BAFF levels were higher in IIM than healthy controls [p = 0.001], and in children with jDM than adults [p = 0.026]. BAFF levels were higher in adults with arthritis [p = 0.018], weight loss [p = 0.007], and PAH [p = 0.004]. Among the various MSAs, lowest levels were seen in those with anti-SRP [p = 0.043]. Median follow-up duration was 145 patient years. Twelve patients relapsed, while nine were in drug-free remission. BAFF were similar between these groups. Serum APRIL levels were elevated in limited number of patients with myositis, and the levels did not differ amongst the clinico-serologic phenotypes. IL-17 levels were higher in individuals positive for anti-SRP [p = 0.028]. Serum BAFF levels are elevated in IIM, more so in children. BAFF levels may be useful as biomarker for PAH and arthritis. Anti-SRP positivity is associated with elevated IL-17 levels suggesting role in pathogenesis.

Entities:  

Keywords:  Autoantibodies; BAFF; Interleukin-17; Myositis

Mesh:

Substances:

Year:  2018        PMID: 29516280     DOI: 10.1007/s10067-018-4046-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  30 in total

1.  Interleukin 17 inhibits myogenic and promotes osteogenic differentiation of C2C12 myoblasts by activating ERK1,2.

Authors:  Jelena Kocić; Juan F Santibañez; Aleksandra Krstić; Slavko Mojsilović; Ivana Okić Dorđević; Drenka Trivanović; Vesna Ilić; Diana Bugarski
Journal:  Biochim Biophys Acta       Date:  2012-01-17

Review 2.  Mortality in idiopathic inflammatory myopathies.

Authors:  I E Lundberg; C J Forbess
Journal:  Clin Exp Rheumatol       Date:  2008 Sep-Oct       Impact factor: 4.473

3.  Interleukin-17 modulates myoblast cell migration by inhibiting urokinase type plasminogen activator expression through p38 mitogen-activated protein kinase.

Authors:  Jelena Kocić; Juan F Santibañez; Aleksandra Krstić; Slavko Mojsilović; Vesna Ilić; Diana Bugarski
Journal:  Int J Biochem Cell Biol       Date:  2012-11-24       Impact factor: 5.085

4.  Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: possible association with myositis?

Authors:  Iman H Bassyouni; Noha A Azab; El-Hussein M El-Dakrony; Marwa M T Fawzi; Randa Ghanoum; Rasha H Bassyouni
Journal:  Joint Bone Spine       Date:  2010-07-06       Impact factor: 4.929

Review 5.  B cell activating factor (BAFF) and BAFF receptors: fakes and facts.

Authors:  G Ferraccioli; E Gremese
Journal:  Clin Exp Immunol       Date:  2017-09-28       Impact factor: 4.330

6.  Contribution of tumour necrosis factor alpha and interleukin (IL) 1beta to IL6 production, NF-kappaB nuclear translocation, and class I MHC expression in muscle cells: in vitro regulation with specific cytokine inhibitors.

Authors:  G Chevrel; C Granet; P Miossec
Journal:  Ann Rheum Dis       Date:  2005-02-24       Impact factor: 19.103

7.  Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines.

Authors:  A Tournadre; V Lenief; P Miossec
Journal:  Arthritis Rheum       Date:  2010-07

Review 8.  B-cell survival factors in autoimmune rheumatic disorders.

Authors:  Sandra A Morais; Andreia Vilas-Boas; David A Isenberg
Journal:  Ther Adv Musculoskelet Dis       Date:  2015-08       Impact factor: 5.346

9.  Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

Authors:  Chester V Oddis; Ann M Reed; Rohit Aggarwal; Lisa G Rider; Dana P Ascherman; Marc C Levesque; Richard J Barohn; Brian M Feldman; Michael O Harris-Love; Diane C Koontz; Noreen Fertig; Stephanie S Kelley; Sherrie L Pryber; Frederick W Miller; Howard E Rockette
Journal:  Arthritis Rheum       Date:  2013-02

10.  B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.

Authors:  Rita A Moura; Cláudia Quaresma; Ana R Vieira; Maria J Gonçalves; Joaquim Polido-Pereira; Vasco C Romão; Nádia Martins; Helena Canhão; João E Fonseca
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more
  1 in total

1.  Serum BAFF and APRIL levels in Indian patients with Takayasu arteritis.

Authors:  Abhishek Zanwar; Avinash Jain; Latika Gupta; Smirti Chaurasia; Sandeep Kumar; Durga Prasanna Misra; Ramnath Misra
Journal:  Clin Rheumatol       Date:  2018-07-11       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.